Amgen Inc (AMGN) SVP sells 2,970 shares after option exercises

Rhea-AI Filing Summary

Amgen Inc. executive Nancy A. Grygiel, SVP & CCO, exercised nonqualified stock options for 1,970 and 1,000 shares of common stock on August 6, 2026, at exercise prices of $177.46 and $177.31 per share, respectively. She then sold 2,970 shares of common stock at $402.1601 per share in reported market transactions. According to the disclosure, the sales included shares used to cover the option exercise price and required withholding taxes related to expiring options. Following these transactions, 106.9449 shares are held indirectly through the company’s 401(k) Plan, and a portion of her reported holdings includes 68 Dividend Equivalents credited to unvested Restricted Stock Units.

Insider Trade Summary

Exercise and Sale: 2,970 shares ($668K approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Grygiel Nancy A.

Role SVP & CCO

Sold 2,970 shs ($1.19M)

Approx. gross sale proceeds $1.19M

Approx. exercise cost $527K

Approx. pre-tax spread $668K

Type	Security	Shares	Price	Value
Exercise	Nqso (Right to Buy)	1,970	$0.00	$0.00
Exercise	Nqso (Right to Buy)	1,000	$0.00	$0.00
Exercise	Common Stock	1,970	$177.46	$350K
Sale	Common Stock F1	1,970	$402.1601	$792K
Exercise	Common Stock	1,000	$177.31	$177K
Sale	Common Stock F1, F2	1,000	$402.1601	$402K
holding	Common Stock F3	--	--	--

Holdings After Transaction: Nqso (Right to Buy) — 2,948 shares (Direct); Common Stock — 7,340 shares (Direct); Common Stock — 106.9449 shares (Indirect, 401(k) Plan)

Footnotes (3)

1. F1. Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
2. F2. These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. F3. These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

Key Figures

Options exercised: 1,970 shares Options exercised: 1,000 shares Shares sold: 1,970 shares +4 more

7 metrics

Options exercised 1,970 shares Nonqualified stock options exercised on 2026-08-06 at $177.46 per share

Options exercised 1,000 shares Nonqualified stock options exercised on 2026-08-06 at $177.31 per share

Shares sold 1,970 shares Common stock sold on 2026-08-06 at $402.1601 per share

Shares sold 1,000 shares Common stock sold on 2026-08-06 at $402.1601 per share

Total shares sold 2,970 shares Aggregate common shares sold per Form 4 transaction summary

401(k) holdings 106.9449 shares Indirect interests in Amgen common stock via the Company’s 401(k) Plan

Dividend Equivalents 68 units Dividend Equivalents credited to unvested Restricted Stock Units

Key Terms

Nqso (Right to Buy), Dividend Equivalents (DEs), Restricted Stock Units, qualifying dividend reinvestment plan, +1 more

5 terms

Nqso (Right to Buy) financial

"Security title listed as "Nqso (Right to Buy)" for option exercises"

Dividend Equivalents (DEs) financial

"These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. plan"

Restricted Stock Units financial

"DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

qualifying dividend reinvestment plan financial

"DEs granted pursuant to the Amgen Inc. plan and subject to a qualifying dividend reinvestment plan"

401(k) Plan financial

"These shares are acquired under the Company's 401(k) Plan and represent interests in the stock fund"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 06:46 PM Accepted by SEC EDGAR 08/07/2026 - 06:45 PM Learn about SEC filing dates

FAQ

What insider transactions did Amgen (AMGN) report for Nancy A. Grygiel?

Amgen (AMGN) reported that SVP & CCO Nancy A. Grygiel exercised stock options for 2,970 shares and sold 2,970 shares of common stock on August 6, 2026. The trades involved option exercises and subsequent share sales at specified prices.

How many Amgen (AMGN) shares did Nancy Grygiel sell and at what price?

Nancy Grygiel sold a total of 2,970 Amgen (AMGN) shares on August 6, 2026, in two transactions of 1,970 and 1,000 shares, each at a price of $402.1601 per share, according to the Form 4 disclosure.

What stock options did the Amgen (AMGN) SVP exercise on August 6, 2026?

On August 6, 2026, the Amgen (AMGN) SVP exercised nonqualified stock options for 1,970 shares at $177.46 per share and 1,000 shares at $177.31 per share. Both option grants related to rights to buy Amgen common stock before their expiration dates.

How were option costs and taxes handled in this Amgen (AMGN) Form 4?

The filing states that the reported sales included shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options, indicating part of the 2,970 shares sold was used for these obligations.

What indirect Amgen (AMGN) holdings does Nancy Grygiel report?

Nancy Grygiel reports indirect holdings of 106.9449 shares of Amgen (AMGN) common stock through the company’s 401(k) Plan. These represent interests in the company’s stock fund as of the filing date, separate from directly held and transacted shares.

What are the Dividend Equivalents mentioned in the Amgen (AMGN) filing?

The Form 4 notes that certain reported holdings include 68 Dividend Equivalents (DEs) credited to unvested Restricted Stock Units. These DEs are paid out in Amgen (AMGN) common shares on a one-to-one basis following the RSUs’ vesting schedule, plus cash for any fractional amount.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grygiel Nancy A.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CCO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		M		1,970	A	$177.46	9,310	D
Common Stock	08/06/2026		S		1,970(1)	D	$402.1601	7,340	D
Common Stock	08/06/2026		M		1,000	A	$177.31	8,340	D
Common Stock	08/06/2026		S		1,000(1)	D	$402.1601	7,340(2)	D
Common Stock								106.9449(3)	I	401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	$177.46	08/06/2026		M			1,970	04/27/2020	04/27/2028	Common Stock	1,970	$0	0	D
Nqso (Right to Buy)	$177.31	08/06/2026		M			1,000	05/03/2021	05/03/2029	Common Stock	1,000	$0	2,948	D

Explanation of Responses:

1. Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

2. These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

3. These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

	/s/ Nancy A. Grygiel	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)